Antianginal drugs such as β-blockers or some calcium antagonists exhibit part of their beneficial effects by reducing heart rate. On the one hand, reduction in heart rate decreases myocardial oxygen demand and on the other hand increases diastolic perfusion time, a major determinant of subendocardial blood flow (Braunwald, 1971) . Indeed, a 1% increase in diastolic time fraction (the quotient of the duration of diastole by the entire heart beat) increases subendocardial flow by 2.6% to 6% in the normal heart (Bache and Cobb, 1977) . In this respect, the development of a selective heart rate reducing agent such as ivabradine, a novel inhibitor of the sino-atrial inward hyperpolarization-activated If current (Thollon et al., 1994 , Vilaine et al., 2003 , is an original alternative approach to β-blockers, as this drug is devoid of any intrinsic negative inotropic effect and does not alter either the global left ventricular systolic and diastolic functions or coronary vasomotion in conscious dogs, both at rest and during exercise (Simon et al., 1995; Colin et al., 2002) . Although it is known that lowering heart rate reduces myocardial oxygen consumption per minute (Boerth et al., 1969), the relationship between the level of heart rate reduction and of MVO 2 remains unknown in vivo.
Accordingly, we investigated the effect of increasing doses of ivabradine at rest and during treadmill exercise on myocardial oxygen consumption and diastolic perfusion time in conscious and chronically instrumented dogs. These responses were also investigated at rest and during exercise while heart rate was kept constant by atrial pacing.
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METHODS
The animal instrumentation and the experiments were performed in accordance with the official regulations of the French Ministry of Agriculture (approval n°A 94-043-12).
Instrumentation
Seven dogs (20-30 kg) were anesthetized with pentobarbital sodium (30 mg/kg i.v.), intubated and ventilated with room air enriched with oxygen (30%). A left thoracotomy was performed through the fifth intercostal space using sterile technique. Fluid-filled Tygon catheters were placed in the descending thoracic aorta and the left atrium. Silastic catheters were implanted in the pulmonary artery and in the coronary sinus. A solid state pressure transducer (P7A, Konigsberg Instruments, Pasadena, CA, USA) was introduced into the apex of the left ventricle. A flow probe (Transonic Systems, Ithaca, NY, USA) was placed on the left circumflex coronary artery for continuous measurement of coronary blood flow.
Piezoelectric ultrasonic dimension crystals were implanted (a) on opposed anterior and posterior endocardial surfaces of the left ventricle to measure left ventricular internal diameter and (b) on opposed left ventricular endocardial and epicardial surfaces to measure wall thickness. Finally, stainless steel wires were sewn to the left atrial appendage for subsequent electrical pacing. All catheters and wires were exteriorized between the scapulae and the pneumothorax was evacuated. Cefazolin (1g, iv) and gentamicin (40 mg, iv) were administered before and during the first week after surgery. Buprenorphine (0.3 mg, sc) was also administered during this period. The position of all catheters and crystals was confirmed at autopsy.
Hemodynamic measurements
This article has not been copyedited and formatted. The final version may differ from this version. where LVP is left ventricular pressure, ID is the internal short-axis diameter and h is wall thickness, each of these parameters being measured at end-systole and end-diastole. The left ventricular peak systolic wall stress was computed as the maximal value of left ventricular wall stress during the ejection period. The integral of the systolic wall stress-time curve socalled mean ejection wall stress was calculated during the ejection period, i.e., from the maximum positive LV dP/dt to the maximum negative LV dP/dt. Percent wall thickening was defined as end-systolic minus end-diastolic thickness divided by end-diastolic thickness x 100.
Left ventricular oxygen consumption
Measurement of oxygen content was made with a blood gas apparatus and a co-oxymeter (BG III synthesis, USA). Oxygen delivery was calculated as the product of mean coronary 
Experimental protocol
The experiments were conducted 3-4 weeks after surgery when the dogs were healthy and apyretic. While the dogs were standing quietly on the treadmill, "baseline" parameters were recorded and blood samples were taken simultaneously from the aorta and the coronary sinus.
A second set of measurements and blood samples collection was performed 15 min after the onset of drugs administration, both at spontaneous heart rate (so-called "Rest") and during a sequence of 5 min of atrial pacing at a rate of 125 beats/min (so-called "Rest paced").
Treadmill exercise (10 km/h, slope 13%, 10 min) was then started. The first 5 min of exercise were performed at spontaneous heart rate, a set of measurements and blood samples collection being performed when a hemodynamic steady state was achieved (so-called "Exercise"). The last 5 min of exercise were performed under atrial pacing at a rate of 250 beats/min (so-called "Exercise-drug paced"), a last set of measurements and blood samples collection being performed at the end of this stage.
Drugs
Each dog underwent four experimental sequences (saline, ivabradine 0.25, 0.5 and 1 mg/kg) which were performed in random order one week apart. Ivabradine (Laboratoires Servier, Neuilly-sur-Seine, France) and saline were administered through the pulmonary artery catheter as an iv bolus. We have previously demonstrated that hemodynamic changes are reproducible when exercises are repeated (Berdeaux et al., 1994) . 
RESULTS
Hemodynamics
As shown in Table 1 , baseline hemodynamics values were not significantly different among the four sequences of the protocol and none of these parameters was altered at rest after saline administration. Ivabradine dose-dependently and significantly reduced heart rate (-16% and -21% at 0.5 and 1 mg/kg, respectively) and increased left ventricular end-diastolic wall stress. These effects were abolished by atrial pacing. Interestingly, ivabradine did not alter left ventricular mean ejection wall stress.
During exercise, the three doses of ivabradine dose-dependently and significantly reduced the exercise-induced tachycardia (-17%, -21% and -32% at 0.25, 0.5 and 1 mg/kg, respectively) and increased both left ventricular end-diastolic pressure and end-diastolic wall stress without changes in left ventricular mean ejection wall stress and LV dP/dt max . These effects were abolished by atrial pacing.
Left ventricular myocardial oxygen consumption
As shown in Table 2 , neither saline nor ivabradine had any effect on resting coronary blood flow or myocardial oxygen balance at spontaneous and paced heart rates. Under saline, MVO 2 during exercise increased 2.7 fold and coronary blood flow increased 1.9 fold from corresponding resting values at spontaneous heart rate. During exercise, ivabradine dosedependently and significantly decreased MVO 2 vs saline (-7.6%, -10.1% and -19% at 0.25, 0.5 and 1 mg/kg, respectively) and these effects were abolished by atrial pacing. Similar 1.4, r=0.987). In addition and as illustrated in figure 2, there were no significant differences among values of O 2 delivery to O 2 consumption ratio among sequences both at rest and during exercise at spontaneous heart rate. Finally, ivabradine significantly increased MVO 2 per beat during exercise (4.2±0.4 and 4.3±0.4 mlO 2 x100/beat at 0.5 and 1 mg/kg, respectively vs 3.6±0.4 mlO 2 x100/beat for saline); this effect was abolished by atrial pacing.
Time intervals
At rest, ivabradine dose-dependently and significantly (0.5 mg/kg; 1 mg/kg) increased both diastolic time and ejection time. These effects were abolished during atrial pacing ( Table 2) .
As shown in figure 3 , an inverse non linear relationship was demonstrated between heart rate (HR) and diastolic time (DT) when all data points were plotted, i.e., saline plus ivabradine.
The relationship between these two parameters was not affected by ivabradine (DT = 884 e 
DISCUSSION
This study investigated the effects of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic perfusion time at rest and during exercise in chronically instrumented normal conscious dogs. Ivabradine is a selective I f channel inhibitor (Thollon et al., 1994 ) that dose-dependently and specifically decreases heart rate during rest and exercise (Simon et al., 1995; Monnet et al., 2001 ) without inducing any other significant hemodynamic alterations in agreement with previous results. A linear relationship was observed between the reduction in heart rate provided by ivabradine and the decrease in MVO 2 . This demonstrates that in this context, one cannot define an optimal dose of ivabradine but rather a wide range of doses that can be used depending on the level of heart rate and/or MVO 2 reduction that needs to be achieved. Finally, heart rate reduction increased the diastolic time and ivabradine did not alter the intrinsic relationship between heart rate and diastolic time.
At all investigated doses, ivabradine did not affect either left ventricular contractility or mean ejection wall stress at rest and during exercise. It is also known that ivabradine does not affect the isovolumic relaxation (Colin et al., 2002 ). An increase in left ventricular filling pressure and in left ventricular end-diastolic wall stress were observed during exercise under ivabradine. This increase in left ventricular end-diastolic pressure was mainly related to the use of preload reserve because of the blunted heart rate response (Paulus et al., 1992) . Indeed, when heart rate was corrected by atrial pacing, left ventricular end-diastolic pressure and wall stress were no longer different than saline. Therefore, the dose-dependent decreases in MVO 2 with ivabradine were mainly related to the sole reduction in heart rate, confirming if necessary, that this If channel inhibitor is totally devoid of intrinsic effect on myocardial contractility.
This article has not been copyedited and formatted. The final version may differ from this version. Regarding the major reductions in heart rate, the related decreases in MVO 2 induced by ivabradine seems not to be as great as expected. This could be explained by the fact that heart rate is not the sole determinant of myocardial oxygen oxygen demand (Braunwald, 1971) .
Furthermore, stroke volume is also one of the correlates of MVO 2 as previously demonstrated
by Rooke and Feigl (1982) . This parameter was not measured in this study but we previously demonstrated that ejection volume was increased after administration of ivabradine in a similar experimental model (Simon et al., 1995) . We can hypothesize that part of the beneficial effects of reducing heart rate on MVO 2 may be partially counteracted by an increase in stroke work. Indeed, MVO 2 per beat was significantly increased with ivabradine.
Nevertheless, we previously demonstrated that such reductions in heart rate were able to exert potent anti-ischemic and anti-stunning effects (Monnet et al., 2001) . Finally, it appears that the effects of ivabradine on MVO 2 depends upon the degree of activation of the autonomic nervous system, i.e., despite significant heart rate reduction with ivabradine, no effect on MVO 2 was observed at rest. Indeed, the slope of the relationship between MVO 2 and heart rate was below the unity (0.044) which means that MVO 2 will be reduced with important changes in heart rate.
In the present study, all changes in MVO 2 were closely related to those of coronary blood flow. The O 2 delivery to O 2 consumption ratio was not significantly affected by ivabradine demonstrating that the normal relationship between oxygen supply and oxygen demand was not modified at rest and during exercise by ivabradine. Indeed, we previously demonstrated that ivabradine does not alter coronary vasomotion at rest and during exercise in normal dogs (Simon et al., 1995) . Finally, as diastolic time is an important determinant of myocardial oxygen supply, we investigated the effect of graded doses of ivabradine on this parameter. For this purpose, diastolic time was plotted against the corresponding heart rate at each stage of the protocol. The diastolic time-heart rate relationship demonstrated an inverse nonlinear exercise. This might be clinically relevant as Ferro et al. (1991b) previously indicated the favorable role of diastolic perfusion time in determining myocardial ischemia. This result also supports the fact that ivabradine is devoid of negative inotropism as it is known that reducing heart rate with β-blockers alters this relationship as a consequence of their negative inotropic effect (Ferro et al., 1991a ).
The present study represents to our knowledge the first one investigating a full doseresponse curve of the effects of a heart rate reducing agent such as ivabradine on MVO 2 . Our study clearly demonstrates a linear relationship between this parameter and the level of heart rate reduction. As ivabradine is devoid of any other hemodynamic properties, i.e., inotropic, lusitropic or vasoactive effects, its administration only acts on heart rate (Simon et al., 1995; Colin et al., 2002) . Interestingly, the effects observed on MVO 2 with increasing doses of ivabradine are progressive and a significant reduction in MVO 2 can be achieved even with small doses at exercise. In another words, ivabradine can exert its pharmacological properties dose-dependently on heart rate and therefore on MVO 2 , within a wide range of doses. This might be clinically relevant as controlling heart rate and diastolic time are major goals to achieve in the treatment of ischemic heart disease. The unique pharmacological profile of ivabradine allows a precise dose adjustment as one can predict the decrease in heart rate and hence in MVO 2 induced by the drug.
In conclusion, ivabradine dose-dependently reduces MVO 2 during exercise demonstrating a linear relationship between heart rate and MVO 2 reductions without any other hemodynamic effects. It also dose-dependently increases the diastolic perfusion time. These pharmacological properties of ivabradine have important clinical implications as its action on both heart rate and diastolic perfusion time is of major importance in the cardioprotective 
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LEGENDS OF FIGURES
Figure 1
Relationship between myocardial oxygen consumption (MVO 2 ) and heart rate (HR) measured at rest and exercise obtained with all data points measured under saline and increasing doses of ivabradine (MVO 2 = 0.044 x HR -1.4, r=0.987).
Figure 2
Relationships between MVO 2 and O 2 delivery to O 2 consumption ratio measured at baseline and during exercise at spontaneous heart rate under saline (open circle) and increasing doses of ivabradine (0.25 mg/kg, closed triangle; 0.5 mg/kg, closed circle; 1 mg/kg, closed square).
Figure 3
Relationship between diastolic time and heart rate demonstrating a curvilinear pattern.
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